116 related articles for article (PubMed ID: 16732573)
1. Efficacy of combination therapy in rheumatoid arthritis: comment on the review by Smolen et al.
Möttönen T; Hannonen P; Leirisalo-Repo M; Korpela M; Hakala M; Kautiainen H;
Arthritis Rheum; 2006 Jun; 54(6):2032-4; author reply 2034-5. PubMed ID: 16732573
[No Abstract] [Full Text] [Related]
2. Folic acid and folinic acid supplementation during low-dose methotrexate therapy for rheumatoid arthritis: comment on the article by van Ede et al.
Morgan SL; Baggott JE; Alarcón GS; Koopman WJ
Arthritis Rheum; 2002 May; 46(5):1413-4. PubMed ID: 12115259
[No Abstract] [Full Text] [Related]
3. Superior efficacy of combination therapy for rheumatoid arthritis: fact or fiction?
Smolen JS; Aletaha D; Keystone E
Arthritis Rheum; 2005 Oct; 52(10):2975-83. PubMed ID: 16200577
[No Abstract] [Full Text] [Related]
4. Limitations of the study of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: comment on the article by Braun et al.
Raghu P; Grover PS; Kumar A
Arthritis Rheum; 2008 Jul; 58(7):2209; author reply 2209-10. PubMed ID: 18576338
[No Abstract] [Full Text] [Related]
5. [Basic therapy of rheumatoid arthritis. 2: Selection, long-term and combination therapy].
Keitel W; Keitel R
MMW Fortschr Med; 1999 Sep; 141(37):42-4. PubMed ID: 10897974
[No Abstract] [Full Text] [Related]
6. Treatment of renal amyloidosis in rheumatoid arthritis requires further investigation: comment on the case report by Elkayam et al.
Ciboddo G; Idone C
Arthritis Rheum; 2003 Nov; 48(11):3299; author reply 3299-300. PubMed ID: 14613302
[No Abstract] [Full Text] [Related]
7. Effects of disease-modifying antirheumatic drug treatment on the expression of RANKL and osteoprotegerin in synovial tissue: comment on the article by Haynes et al.
Catrina AI; Klareskog L
Arthritis Rheum; 2008 Nov; 59(11):1685; author reply 1685-6. PubMed ID: 18975354
[No Abstract] [Full Text] [Related]
8. Effect of folic acid supplementation on the efficacy of methotrexate treatment in rheumatoid arthritis: comment on the article by Khanna et al.
Morgan SL; Baggott JE; Alarcón GS
Arthritis Rheum; 2006 May; 54(5):1708-9; author reply 1709-10. PubMed ID: 16646062
[No Abstract] [Full Text] [Related]
9. [Reconsideration of glucocorticoid therapy for rheumatoid arthritis].
Ichikawa Y
Ryumachi; 2002 Dec; 42(6):859-62. PubMed ID: 12632604
[No Abstract] [Full Text] [Related]
10. Short-term effects of rituximab on flow-mediated dilatation may be mediated by intravenous glucocorticoids: comment on the article by Gonzalez-Juanatey et al.
Sandoo A; Toms T; Zanten JV; Carroll D; Kitas G
Arthritis Rheum; 2009 Jun; 61(6):854-5; author reply 855-6. PubMed ID: 19479694
[No Abstract] [Full Text] [Related]
11. Inclusion of glucocorticoids in recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis: Comment on the article by Saag et al.
van Tuyl LH; Lems WF; Voskuyl AE; Dijkmans BA; Boers M; Kerstens PJ
Arthritis Rheum; 2009 Jan; 61(1):141-2; author reply 141-2. PubMed ID: 19116962
[No Abstract] [Full Text] [Related]
12. Drugs for rheumatoid arthritis.
Treat Guidel Med Lett; 2009 May; 7(81):37-46; quiz 47-8. PubMed ID: 19390497
[No Abstract] [Full Text] [Related]
13. Intra-articular infliximab in patients with rheumatoid arthritis and psoriatic arthritis with monoarthritis resistant to local glucocorticoids. Clinical efficacy extended to patients on systemic anti-tumour necrosis factor alpha.
Conti F; Ceccarelli F; Priori R; Iagnocco A; Signore A; Valesini G
Ann Rheum Dis; 2008 Dec; 67(12):1787-90. PubMed ID: 19005158
[No Abstract] [Full Text] [Related]
14. Cyclosporine and tacrolimus for the treatment of rheumatoid arthritis.
Kitahara K; Kawai S
Curr Opin Rheumatol; 2007 May; 19(3):238-45. PubMed ID: 17414949
[TBL] [Abstract][Full Text] [Related]
15. The use of glucocorticoids in preventing joint destruction: Comment on the review by Schett et al.
Kirwan JR; Boers Msc M
Arthritis Rheum; 2009 Apr; 60(4):1202-3; reply 1203-4. PubMed ID: 19333941
[No Abstract] [Full Text] [Related]
16. The case against haste in the treatment of rheumatoid arthritis: comment on the editorial by Pincus et al.
Epstein WV
Arthritis Rheum; 2003 Feb; 48(2):573-5; author reply 576-9. PubMed ID: 12571870
[No Abstract] [Full Text] [Related]
17. Trials in rheumatoid arthritis: choosing the right outcome measures--comment on the article by Felson et al.
Porter D
Ann Rheum Dis; 2008 Sep; 67(9):1356. PubMed ID: 18697785
[No Abstract] [Full Text] [Related]
18. Comment on: British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of rheumatoid arthritis (after the first 2 years).
McLaren ZL; Abernethy VE; Dawson JK
Rheumatology (Oxford); 2009 Sep; 48(9):1178-9; author reply 1179. PubMed ID: 19578135
[No Abstract] [Full Text] [Related]
19. [Comparison of efficacy and tolerability of triple combination therapy (methotrexate + sulfasalazine + hydroxychloroquine) with methotrexate monotherapy in patients with rheumatoid arthritis].
Gubar' EE; Bochkova AG; Bunchuk NV
Ter Arkh; 2008; 80(5):25-30. PubMed ID: 18590110
[TBL] [Abstract][Full Text] [Related]
20. Infusion reaction to infliximab in a patient with rheumatoid arthritis after discontinuation over 1 year and readministration.
Toki H; Momohara S; Tsukahara S; Ikari K
J Rheumatol; 2008 Sep; 35(9):1896-7; author reply 1897. PubMed ID: 18785300
[No Abstract] [Full Text] [Related]
[Next] [New Search]
